JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

UPP1 and AHSA1 as emerging biomarkers and targets in pancreatic cancer: A proteomic approach

  • 0Department of Pancreatic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Biomolecules & Biomedicine +

|

May 13, 2025

|

May 13, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study identifies Uridine Phosphorylase 1 (UPP1) and Activator of HSP90 ATPase Activity 1 (AHSA1) as key proteins in pancreatic cancer progression and differentiation. These proteins show potential as diagnostic markers and therapeutic targets for pancreatic cancer.

Area Of Science

  • Proteomics and Bioinformatics
  • Cancer Biology
  • Molecular Oncology

Background

  • Pancreatic cancer (PC) pathogenesis and differentiation mechanisms are not fully understood.
  • Advanced proteomic methods can identify key proteins and pathways in cancer progression.

Purpose Of The Study

  • To identify differentially expressed proteins (DEPs) in pancreatic cancer tissues compared to adjacent non-cancerous tissues.
  • To investigate DEPs associated with pancreatic cancer differentiation.
  • To validate potential diagnostic and therapeutic targets.

Main Methods

  • Proteomic analysis of PC and para-PC tissues.
  • Bioinformatics for DEP identification and pathway analysis.
  • Validation using GEPIA, RT-qPCR, Western blotting, IHC, and IF.

Main Results

  • Identified 431 DEPs between PC and para-PC tissues.
  • Identified 470 DEPs distinguishing poorly differentiated (PD) from moderately differentiated (MD) PCs.
  • Uridine Phosphorylase 1 (UPP1) and Activator of HSP90 ATPase Activity 1 (AHSA1) were significantly upregulated in PC and PD-PCs.

Conclusions

  • UPP1 and AHSA1 are key proteins linked to pancreatic cancer differentiation and progression.
  • These proteins represent potential diagnostic markers and therapeutic targets for PC.
  • Findings advance understanding of PC molecular mechanisms for precision medicine.